Ignite Creation Date:
2024-05-05 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00274352
Status:
COMPLETED
Last Update Posted:
2013-05-22
First Post:
2006-01-06
Brief Title:
A Study of Adalimumab to Treat Sarcoidosis of the Skin
Sponsor:
Pariser Robert J MD
Organization:
Pariser Robert J MD
Study Overview
Official Title:
A Double-Blind Randomized Placebo-Controlled Study of Adalimumab in the Treatment of Cutaneous Sarcoidosis
Status:
COMPLETED
Status Verified Date:
2013-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if adalimumab is an effective for the skin manifestations of sarcoidosis
Detailed Description:
The cutaneous lesions of sarcoidosis are often disfiguring and can produce functional impairment They tend to be hard to treat with most topical therapies and often require systemic medications which carry the risk of significant side effects Often such treatments are withheld unless there is a need to use them for visceral involvement There is thus an unmet need for safe and effective treatments for these patients In addition there is essentially no controlled trial data for any treatments for cutaneous sarcoidosis This study is intended to determine if adalimumab might offer a viable therapeutic option for this condition by comparing the response of cutaneous sarcoid lesions to this drug as compared to placebo
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None